Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Report Calls For Pushing And Pulling In Global Fight Against Superbugs

Executive Summary

New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.

Advertisement

Related Content

Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts
Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts
Fix Antibiotic Payment Models To Spur R&D Investment, US FDA’s Gottlieb Says
Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups
O'Neill: UK 'Lost Focus' On Antibiotic Crisis And Pharma Must Do More
Antibiotic Incentives: Prize Fund Is Focus Of Presidential Report On Incentives
AMR Roundtable: Optimism About CARB-X's Success And Prospects For The Future (Part 2)
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
CARB-X Partnership Puts Antibiotics' Future In Biotech Startups' Hands
Global Fund For Antimicrobial Resistance Proposed, Financing Unclear

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100264

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel